NONOF — NOVO NORDISK A S
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 353278 ·
Last close
$38.66
Market Cap
$129.28B
52W High
$62.56
52W Low
$33.39
ADV30
132,427
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 78,488,000,000 | 61,388,000,000 | 27,061,000,000 | 20,989,000,000 | 594,941,000,000 | 44,482,000,000 | 373,664,000,000 |
| Mar 2026 | 96,823,000,000 | 83,225,000,000 | 59,618,000,000 | 48,557,000,000 | 559,221,000,000 | 21,127,000,000 | 356,156,000,000 |
| Dec 2025 | 79,144,000,000 | 63,996,000,000 | 31,736,000,000 | 26,891,000,000 | 542,902,000,000 | 26,464,000,000 | 348,855,000,000 |
| Sep 2025 | 74,976,000,000 | 57,072,000,000 | 23,682,000,000 | 20,006,000,000 | 512,288,000,000 | 32,084,000,000 | 342,392,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$131,881,000,000
Investing CF
$-83,537,000,000
Financing CF
$-22,242,000,000
CapEx
$-84,092,000,000
Dividends Paid
$-51,975,000,000
Buybacks
$-5,899,000,000
EPS Diluted TTM
$27.65
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$224,164,000,000
Inventory
$51,352,000,000
Receivables
$108,512,000,000
ST Investments
$500,000,000
EBIT TTM
$149,464,000,000
Pretax Income TTM
$148,749,000,000
Interest Exp TTM
$5,551,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$329,430,990,848
EBITDA
$173,677,002,752
Free Cash Flow
$37,673,250,816
Enterprise Value
$286,392,877,056
Total Cash
$44,982,001,664
Total Debt
$140,126,994,432
Shares Out
3,344,053,124
Trailing EPS
$4.09
Book Value
$7.74
ROE
59.8%
ROA
18.7%
Div Yield
4.17%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 309,064,000,000 | 127,658,000,000 | 102,434,000,000 | 542,902,000,000 | 348,855,000,000 | 194,047,000,000 | 119,102,000,000 |
| Dec 2024 | 290,403,000,000 | 128,339,000,000 | 100,988,000,000 | 465,630,000,000 | 322,144,000,000 | 143,486,000,000 | 120,968,000,000 |
| Dec 2023 | 232,261,000,000 | 102,574,000,000 | 83,683,000,000 | 314,486,000,000 | 207,925,000,000 | 106,561,000,000 | 108,908,000,000 |
| Dec 2022 | 176,954,000,000 | 74,809,000,000 | 55,525,000,000 | 241,257,000,000 | 157,771,000,000 | 83,486,000,000 | 78,887,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVO | NOVO NORDISK A S | $129.45B | $38.71 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $130.49B | $63.88 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $133.74B | $527.67 | — |
| PFE | PFIZER INC | $163.69B | $28.72 | — |
| GSK | GSK plc | $99.54B | $49.70 | — |
News headlines (Yahoo Finance, 1h cache)
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal
2026-09-29 05:46 · Yahoo
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
2026-09-29 04:35 · Yahoo
Can Novo Nordisk (NVO) Turn Monthly Dosing into Growth?
2026-09-29 00:21 · Yahoo
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
2026-09-28 19:55 · Yahoo
Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
2026-09-28 18:31 · Yahoo
Novo Nordisk A/S - share repurchase programme
2026-09-28 13:50 · Yahoo
Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come
2026-09-28 12:12 · Yahoo
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
2026-09-28 03:31 · Yahoo
Can Novo Nordisk (NVO) Find a Second Act Before its First One Fades?
2026-09-28 01:55 · Yahoo
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-27 22:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.